Plasma TNFSF10 levels associated with acamprosate treatment response in patients with alcohol use disorder.
Plasma TNFSF10 levels associated with acamprosate treatment response in patients with alcohol use disorder.
复制标题
DOI：
10.3389/fphar.2022.986238
复制
发表时间：
2022
影响因子：
5.6
通讯作者：
中科院分区：
文献类型：
--
作者：
氨基己酸酯是一种用于酒精使用障碍(AUD)药物治疗的抗瘾药物。然而，只有一小部分患者实现了最佳治疗结果。AUD患者醋氨己酯治疗反应的预测生物标志物的确定将是成瘾医学的重大进步。我们设计这项研究是为了使用蛋白质组学数据作为一个定量的生物学特征，以此作为识别可能与阿司匹林治疗结果相关的炎症调节因子的一步。NIAAA资助的梅奥临床酒精中毒个体化治疗研究中心此前招募了442名AUD患者，他们接受了为期3个月的阿卡米松治疗。然而，只有267名受试者返回进行为期3个月的随访，结果是获得了治疗结果信息。基线酒精渴求强度是氨基己酸酯治疗结果的最显著预测因素。我们使用Olink Target 96炎症小组进行了血浆蛋白质组学研究，发现基线血浆肿瘤坏死因子超家族成员10(TNFSF10)浓度与AUD患者的酒精渴求强度和氨基己酸酯治疗结果的差异有关。我们还使用AUD患者的基线外周血单核细胞进行了RNA测序，结果表明，在AUD治疗的3个月期间，炎症相关途径与酒精复发高度相关。这些观察结果代表着促进我们对AUD的病理生理学和与氨基己酸酯治疗反应相关的分子机制的理解的重要一步。总之，应用基于组学的方法可能是一种实用的方法来识别可能预测酒精渴求强度和氨基己酸酯治疗反应的生物标记物。
Acamprosate is an anti-craving drug used in alcohol use disorder (AUD) pharmacotherapy. However, only a subset of patients achieves optimal treatment outcomes. The identification of predictive biomarkers of acamprosate treatment response in patients with AUD would be a substantial advance in addiction medicine. We designed this study to use proteomics data as a quantitative biological trait as a step toward identifying inflammatory modulators that might be associated with acamprosate treatment outcomes. The NIAAA-funded Mayo Clinic Center for the Individualized Treatment of Alcoholism study had previously recruited 442 AUD patients who received 3 months of acamprosate treatment. However, only 267 subjects returned for the 3-month follow-up visit and, as a result, had treatment outcome information available. Baseline alcohol craving intensity was the most significant predictor of acamprosate treatment outcomes. We performed plasma proteomics using the Olink target 96 inflammation panel and identified that baseline plasma TNF superfamily member 10 (TNFSF10) concentration was associated with alcohol craving intensity and variation in acamprosate treatment outcomes among AUD patients. We also performed RNA sequencing using baseline peripheral blood mononuclear cells from AUD patients with known acamprosate treatment outcomes which revealed that inflammation-related pathways were highly associated with relapse to alcohol use during the 3 months of acamprosate treatment. These observations represent an important step toward advancing our understanding of the pathophysiology of AUD and molecular mechanisms associated with acamprosate treatment response. In conclusion, applying omics-based approaches may be a practical approach for identifying biologic markers that could potentially predict alcohol craving intensity and acamprosate treatment response.
登录
查看更多内容
影响因子：
6.8
作者：
Nam HW;Karpyak VM;Hinton DJ;Geske JR;Ho AM;Prieto ML;Biernacka JM;Frye MA;Weinshilboum RM;Choi DS
通讯作者：
Choi DS
DOI：
10.1111/j.1530-0277.2011.01616.x
发表时间：
2012-03-01
影响因子：
3.2
作者：
Mason, Barbara J.;Lehert, Philippe
通讯作者：
Lehert, Philippe
影响因子：
--
作者：
Ho, Ming-Fen;Bongartz, Tim;Weinshilboum, Richard M.
通讯作者：
Weinshilboum, Richard M.
影响因子：
5.6
作者：
Ho, Ming-Fen;Zhang, Cheng;Weinshilboum, Richard M.
通讯作者：
Weinshilboum, Richard M.
影响因子：
5.5
作者：
Lira, Marlene C.;Sarda, Vishnudas;Naimi, Timothy S.
通讯作者：
Naimi, Timothy S.